Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors, antagonists |
Mechanism COX inhibitors(Cyclooxygenases inhibitors), Opioid receptors antagonists(Opioid receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H24ClNO4 |
InChIKeyRHBRMCOKKKZVRY-ITLPAZOVSA-N |
CAS Registry16676-29-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Low Back Pain | Phase 1 | United States | 15 Aug 2017 | |
Migraine Disorders | Phase 1 | United States | 18 Feb 2017 | |
Adjustment disorders | Phase 1 | - | - |
Phase 2 | 12 | (Low-Dose Naltrexone and Acetaminophen Combination) | tovabfwryw(fjulbyoszb) = dauqzevpwe citbvqbyox (kmtzdqwapr, iuaybugfdg - baapdnrfuo) View more | - | 10 Apr 2024 | ||
Placebo (Placebo) | tovabfwryw(fjulbyoszb) = vgdliewxhb citbvqbyox (kmtzdqwapr, nzbbskvdnl - brexjyvsuw) View more |